Maxim Group Remains a Buy on Moleculin Biotech (MBRX)


Maxim Group analyst Jason McCarthy reiterated a Buy rating on Moleculin Biotech (MBRX) yesterday and set a price target of $18.00. The company’s shares closed last Wednesday at $4.75.

According to TipRanks.com, McCarthy is a top 25 analyst with an average return of 64.3% and a 65.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group.

Currently, the analyst consensus on Moleculin Biotech is a Strong Buy with an average price target of $8.33.

See today’s analyst top recommended stocks >>

Moleculin Biotech’s market cap is currently $66.52M and has a P/E ratio of -2.40. The company has a Price to Book ratio of 3.38.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company’s preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts